Skip to main content

Alison H. Peters

Associate

[email protected]

+1.202.434.7335

Share:

Alison counsels a broad range of healthcare and life sciences clients on regulatory, compliance, transactional, and legislative matters. Her clients include pharmacy benefit managers (PBMs), national and regional payors, pharmaceutical and medical device manufacturers, private equity firms, physician practice groups, hospital systems, clinical laboratories, diagnostic testing facilities, and trade groups. 

Specifically, Alison focuses on complex transactions, fraud and abuse, and market access issues.  Alison has experience representing clients in investigations and proceedings by government entities, including the Center for Medicare & Medicaid Services, and the US Department of Health and Human Services Office of Inspector General, and Congressional committees. Clients also seek her guidance on internal compliance investigations and enforcement matters and navigating complex value-based arrangements.   

Prior to joining Mintz, Alison was an associate at a multinational law firm, where she handled a wide range of health care regulatory and transactional matters. 

While earning her JD, Alison served as an executive online editor of the Georgetown Journal of International Law and clerked in a plaintiffs’-side False Claims Act practice. She also studied at Keio University in Tokyo, Japan, where she focused on corporate l law. 

Before law school, Alison led advertising strategy for Fortune 500 consumer and health care brands.
 

viewpoints

The PBM Policy and Legislative Update — Winter 2025 edition builds upon prior PBM Policy and Legislative Updates and summarizes activity from October through December (2024) that affects the PBM industry. It highlights (i) federal activities, (ii) state activities, and (iii) other noteworthy events and trends affecting the PBM industry.

Read more

Building upon prior issues and summarizing activity from July through September, the Fall 2024 PBM Update highlights federal legislative activity and oversight, state legislative activity and oversight, and other noteworthy events and trends affecting the PBM industry.

Read more

On August 15, 2024, CMS announced the results of the first round of the negotiated prices between CMS and participating drug manufacturers for the 10 selected drugs under the Inflation Reduction Act’s (IRA) Medicare Drug Price Negotiation Program (MPN or Program). In all, reactions to the MPN results varied: Reuters reported that executives from four of the manufacturers selected in the first round of negotiations stated that they do not expect the negotiated prices to significantly impact their businesses; meanwhile, in its press release announcing the maximum fair prices (MFPs), CMS touted an estimated $1.5 billion in Medicare prescription drug out-of-pocket cost savings for Medicare beneficiaries when the negotiated prices go into effect in 2026. 

Read more
Read less

podcasts

Host Of Counsel Bridgette Keller invites the Mintz Health Law team to reflect on what they’re grateful for as they prepare for the year ahead. Hear from a dynamic group of Members, Of Counsel, and Associates as they share their perspectives on what’s coming up over the horizon.

Read more
Read less

Involvement

  • American Bar Association, Health Law Section
  • Health Law Committee, District of Columbia Bar Association (Oct. 2023 – June 2024)
  • New York Bar (2019 – present)
  • District of Columbia Bar Association (2020 – present)
Read less